NO324881B1 - Anvendelse av en stamme av Lactobacillus for fremstilling av et medikament for profylakse og/eller behandling av sirkulatoriske sykdommer. - Google Patents
Anvendelse av en stamme av Lactobacillus for fremstilling av et medikament for profylakse og/eller behandling av sirkulatoriske sykdommer. Download PDFInfo
- Publication number
- NO324881B1 NO324881B1 NO20000268A NO20000268A NO324881B1 NO 324881 B1 NO324881 B1 NO 324881B1 NO 20000268 A NO20000268 A NO 20000268A NO 20000268 A NO20000268 A NO 20000268A NO 324881 B1 NO324881 B1 NO 324881B1
- Authority
- NO
- Norway
- Prior art keywords
- lactobacillus
- strain
- fibrinogen
- prophylaxis
- treatment
- Prior art date
Links
- 241000186660 Lactobacillus Species 0.000 title claims description 23
- 229940039696 lactobacillus Drugs 0.000 title claims description 20
- 239000003814 drug Substances 0.000 title claims description 10
- 238000004519 manufacturing process Methods 0.000 title claims description 9
- 201000010099 disease Diseases 0.000 title claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 8
- 238000011282 treatment Methods 0.000 title claims description 7
- 238000011321 prophylaxis Methods 0.000 title claims description 6
- 229940079593 drug Drugs 0.000 title description 7
- 108010049003 Fibrinogen Proteins 0.000 claims description 30
- 102000008946 Fibrinogen Human genes 0.000 claims description 30
- 229940012952 fibrinogen Drugs 0.000 claims description 30
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 9
- 206010014476 Elevated cholesterol Diseases 0.000 claims description 6
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 6
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 5
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 5
- 208000031225 myocardial ischemia Diseases 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 208000029078 coronary artery disease Diseases 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 30
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 235000012000 cholesterol Nutrition 0.000 description 9
- 235000007319 Avena orientalis Nutrition 0.000 description 7
- 244000075850 Avena orientalis Species 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 108010010234 HDL Lipoproteins Proteins 0.000 description 5
- 102000015779 HDL Lipoproteins Human genes 0.000 description 5
- 238000008214 LDL Cholesterol Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 240000001046 Lactobacillus acidophilus Species 0.000 description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 230000003480 fibrinolytic effect Effects 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 210000005095 gastrointestinal system Anatomy 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FCSSPCOFDUKHPV-UHFFFAOYSA-N 2-Propenyl propyl disulfide Chemical compound CCCSSCC=C FCSSPCOFDUKHPV-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010088842 Fibrinolysin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000000871 hypocholesterolemic effect Effects 0.000 description 2
- 229960000448 lactic acid Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 101150102415 Apob gene Proteins 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- -1 LDL cholesterol Chemical class 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000021015 bananas Nutrition 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940001501 fibrinolysin Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000019895 oat fiber Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/853—Lactobacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/853—Lactobacillus
- Y10S435/856—Lactobacillus casei
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/853—Lactobacillus
- Y10S435/857—Lactobacillus plantarum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9702860A SE510753C2 (sv) | 1997-08-05 | 1997-08-05 | Användning av en stam av Lactobacillus för tillverkning av ett läkemedel för reduktion av fibrinogenhalten i blod |
| PCT/SE1998/001423 WO1999007827A1 (en) | 1997-08-05 | 1998-07-30 | Use of lactobacillus for reduction of the fibrinogen level in blood |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20000268D0 NO20000268D0 (no) | 2000-01-19 |
| NO20000268L NO20000268L (no) | 2000-01-19 |
| NO324881B1 true NO324881B1 (no) | 2007-12-27 |
Family
ID=20407874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20000268A NO324881B1 (no) | 1997-08-05 | 2000-01-19 | Anvendelse av en stamme av Lactobacillus for fremstilling av et medikament for profylakse og/eller behandling av sirkulatoriske sykdommer. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6214336B1 (pl) |
| EP (1) | EP0990024B1 (pl) |
| JP (1) | JP4651814B2 (pl) |
| KR (1) | KR100517755B1 (pl) |
| CN (1) | CN1142995C (pl) |
| AR (1) | AR016798A1 (pl) |
| AT (1) | ATE326524T1 (pl) |
| AU (1) | AU729413B2 (pl) |
| BR (1) | BR9811825A (pl) |
| CA (1) | CA2297023C (pl) |
| DE (1) | DE69834560T2 (pl) |
| ES (1) | ES2259457T3 (pl) |
| IL (1) | IL134113A0 (pl) |
| NO (1) | NO324881B1 (pl) |
| NZ (1) | NZ502610A (pl) |
| PL (1) | PL194697B1 (pl) |
| SE (1) | SE510753C2 (pl) |
| WO (1) | WO1999007827A1 (pl) |
| ZA (1) | ZA986769B (pl) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1117414A1 (en) | 1998-10-01 | 2001-07-25 | Probi Ab | Reduction of oxidative stress factors |
| JP4193269B2 (ja) * | 1999-03-04 | 2008-12-10 | ビーエイチピーエイチ カンパニーリミテッド | 新規な生体浄化活性型乳酸菌製剤 |
| SE523771C2 (sv) * | 1999-05-21 | 2004-05-18 | Probi Ab | Sportdryck innehållande mikronäringsämnen i kombination med levande laktobaciller |
| AUPR101600A0 (en) * | 2000-10-25 | 2000-11-16 | Atheromastat Pty Ltd | Compositions and methods for diagnosis and treatment of cardiovascular disorders |
| SE0004124D0 (sv) * | 2000-11-10 | 2000-11-10 | Probi Ab | New use |
| GB0124580D0 (en) * | 2001-10-12 | 2001-12-05 | Univ Reading | New composition |
| KR20030033950A (ko) * | 2001-10-20 | 2003-05-01 | 주식회사 알엔에이 | 유산균 세포질 분획물 또는 유산균 파쇄물을 유효성분으로포함하는 동맥경화 억제제 |
| FR2831395B1 (fr) * | 2001-10-25 | 2004-06-11 | Triballat Laiteries | Procede de fabrication de produits fermentes a base de soja, produits fermentes obtenus par ce procede et ferments correspondants |
| TWI241912B (en) * | 2002-10-30 | 2005-10-21 | Food Industry Res & Dev Inst | Novel Acid-and bile salt-resistant Lactobacillus isolates having the ability to lower and assimilate cholesterol |
| SE527555C2 (sv) * | 2003-04-04 | 2006-04-11 | Probi Ab | Anti-inflammatorisk komposition innehållande tannasproducerande Lactobacillusstammar |
| CN1207382C (zh) * | 2003-04-11 | 2005-06-22 | 上海光明乳业股份有限公司 | 植物乳杆菌st－iii菌株及其在调节血脂方面的应用 |
| US8877178B2 (en) | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
| US20050158294A1 (en) | 2003-12-19 | 2005-07-21 | The Procter & Gamble Company | Canine probiotic Bifidobacteria pseudolongum |
| US7001756B1 (en) * | 2004-02-19 | 2006-02-21 | Genmont Biotech Inc. | Microorganism strain of GM-020 of Lactobacillus rhamnosus and its use for treating obesity |
| GB0424552D0 (en) * | 2004-11-05 | 2004-12-08 | Cambridge Theranostics Ltd | Methods and means |
| AR053805A1 (es) | 2005-05-31 | 2007-05-23 | Iams Company | Bifidobacterias probioticas para felinos |
| EP2261323A1 (en) | 2005-05-31 | 2010-12-15 | The Iams Company | Feline probiotic lactobacilli |
| US20080254011A1 (en) * | 2007-04-11 | 2008-10-16 | Peter Rothschild | Use of selected lactic acid bacteria for reducing atherosclerosis |
| KR100909586B1 (ko) * | 2007-06-01 | 2009-07-27 | 신현길 | 혈중 콜레스테롤 농도 저하에 효과적인 유산균 및 이들의혼합균주 |
| SE532899C2 (sv) * | 2007-06-08 | 2010-05-04 | Probi Ab | Förfarande genom fermentering med Lactobacillus plantarum för tillhandahållande av en insulinsvarsreducerande produkt och dess användning farmaceutiskt eller i livsmedel |
| JP5469873B2 (ja) * | 2008-03-11 | 2014-04-16 | 株式会社日立製作所 | 回転電機 |
| US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
| JP5140791B2 (ja) * | 2008-11-27 | 2013-02-13 | 森下仁丹株式会社 | 乳酸菌含有血中ホモシステイン低減剤 |
| WO2010096550A2 (en) | 2009-02-18 | 2010-08-26 | University Of Florida Research Foundation, Inc. | Lactobacillus supplement for alleviating type 1 diabetes |
| CN104784219A (zh) * | 2009-06-19 | 2015-07-22 | 杜邦营养生物科学有限公司 | 治疗糖尿病及相关病症的双歧杆菌 |
| US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
| CN102031229B (zh) * | 2009-09-24 | 2012-05-30 | 家医国际生化股份有限公司 | 具有肠胃道吸附能力及排除胆固醇能力的植物乳杆菌 |
| ES2587136T3 (es) * | 2010-01-08 | 2016-10-20 | Compagnie Gervais Danone | Lactobacilos con acción antioxidante |
| GB201319540D0 (en) * | 2013-11-05 | 2013-12-18 | Optibiotix Health Ltd | Composition |
| GB201319538D0 (en) | 2013-11-05 | 2013-12-18 | Optibiotix Health Ltd | Composition |
| GB201709763D0 (en) | 2017-06-19 | 2017-08-02 | Probi Ab | Biological materials and methods |
| CN110786435B (zh) * | 2019-11-19 | 2022-08-23 | 四川农业大学 | 产高活性纤溶酶原激活剂的植物乳杆菌及用其发酵的果蔬汁饮料 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0647551B2 (ja) * | 1986-12-01 | 1994-06-22 | 株式会社ヤクルト本社 | 血圧降下剤 |
| JP2676250B2 (ja) * | 1989-03-20 | 1997-11-12 | 株式会社ヤクルト本社 | 血圧降下剤およびその製造法 |
| JP2855290B2 (ja) * | 1990-11-30 | 1999-02-10 | 株式会社ヤクルト本社 | 脂質代謝改善剤 |
| JPH04264034A (ja) * | 1991-02-18 | 1992-09-18 | Snow Brand Milk Prod Co Ltd | 生体内過酸化脂質抑制剤 |
| JPH0525055A (ja) * | 1991-07-22 | 1993-02-02 | Yakult Honsha Co Ltd | 血圧降下剤 |
| SE469875C (sv) * | 1991-07-25 | 1997-04-14 | Probi Ab | Stam av tarmkoloniserande Lactobacillus samt komposition för profylax eller behandling av infektioner i magtarmkanalen |
| JPH06116155A (ja) * | 1992-10-08 | 1994-04-26 | Yakult Honsha Co Ltd | 血清コレステロール低下剤 |
| JP2801479B2 (ja) * | 1992-10-09 | 1998-09-21 | 株式会社トクヤマ | 補綴材料の製造方法 |
| JP2992945B2 (ja) * | 1994-03-11 | 1999-12-20 | カルピス株式会社 | ラクトバチルス・アシドフィルス乳酸菌 |
| JPH08208512A (ja) * | 1995-02-03 | 1996-08-13 | Nippon Chem Res Kk | 血栓形成阻害剤 |
-
1997
- 1997-08-05 SE SE9702860A patent/SE510753C2/sv not_active IP Right Cessation
-
1998
- 1998-07-29 ZA ZA986769A patent/ZA986769B/xx unknown
- 1998-07-30 JP JP2000506312A patent/JP4651814B2/ja not_active Expired - Lifetime
- 1998-07-30 AT AT98934131T patent/ATE326524T1/de not_active IP Right Cessation
- 1998-07-30 PL PL98338578A patent/PL194697B1/pl unknown
- 1998-07-30 KR KR10-2000-7001211A patent/KR100517755B1/ko not_active IP Right Cessation
- 1998-07-30 BR BR9811825-0A patent/BR9811825A/pt not_active Application Discontinuation
- 1998-07-30 CA CA2297023A patent/CA2297023C/en not_active Expired - Lifetime
- 1998-07-30 WO PCT/SE1998/001423 patent/WO1999007827A1/en active IP Right Grant
- 1998-07-30 IL IL13411398A patent/IL134113A0/xx not_active IP Right Cessation
- 1998-07-30 US US09/485,190 patent/US6214336B1/en not_active Expired - Lifetime
- 1998-07-30 EP EP98934131A patent/EP0990024B1/en not_active Expired - Lifetime
- 1998-07-30 NZ NZ502610A patent/NZ502610A/xx not_active IP Right Cessation
- 1998-07-30 ES ES98934131T patent/ES2259457T3/es not_active Expired - Lifetime
- 1998-07-30 AU AU83726/98A patent/AU729413B2/en not_active Expired
- 1998-07-30 CN CNB988076357A patent/CN1142995C/zh not_active Expired - Lifetime
- 1998-07-30 DE DE69834560T patent/DE69834560T2/de not_active Expired - Lifetime
- 1998-08-05 AR ARP980103872A patent/AR016798A1/es not_active Application Discontinuation
-
2000
- 2000-01-19 NO NO20000268A patent/NO324881B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IL134113A0 (en) | 2001-04-30 |
| JP2001512747A (ja) | 2001-08-28 |
| JP4651814B2 (ja) | 2011-03-16 |
| ZA986769B (en) | 1999-02-02 |
| CN1142995C (zh) | 2004-03-24 |
| KR100517755B1 (ko) | 2005-09-30 |
| DE69834560T2 (de) | 2006-11-02 |
| PL338578A1 (en) | 2000-11-06 |
| CN1265141A (zh) | 2000-08-30 |
| PL194697B1 (pl) | 2007-06-29 |
| NZ502610A (en) | 2000-12-22 |
| DE69834560D1 (de) | 2006-06-22 |
| EP0990024B1 (en) | 2006-05-17 |
| SE510753C2 (sv) | 1999-06-21 |
| US6214336B1 (en) | 2001-04-10 |
| SE9702860L (sv) | 1999-02-06 |
| WO1999007827A1 (en) | 1999-02-18 |
| NO20000268D0 (no) | 2000-01-19 |
| AU8372698A (en) | 1999-03-01 |
| ATE326524T1 (de) | 2006-06-15 |
| AR016798A1 (es) | 2001-08-01 |
| NO20000268L (no) | 2000-01-19 |
| KR20010022617A (ko) | 2001-03-26 |
| SE9702860D0 (sv) | 1997-08-05 |
| AU729413B2 (en) | 2001-02-01 |
| CA2297023C (en) | 2010-03-30 |
| CA2297023A1 (en) | 1999-02-18 |
| EP0990024A1 (en) | 2000-04-05 |
| BR9811825A (pt) | 2000-08-15 |
| ES2259457T3 (es) | 2006-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO324881B1 (no) | Anvendelse av en stamme av Lactobacillus for fremstilling av et medikament for profylakse og/eller behandling av sirkulatoriske sykdommer. | |
| US20240285695A1 (en) | Treatment of Obesity, the Metabolic Syndrome, Type 2 Diabetes, Cardiovascular Diseases, Dementia, Alzheimer's Disease and Inflammatory Bowel Disease by using at Least one Bacterial Strain from Prevotella | |
| CN100421676C (zh) | 乳酸产生细菌和肺功能 | |
| Zoppi et al. | The intestinal ecosystem in chronic functional constipation | |
| JP4203855B2 (ja) | 乳酸菌を有効成分とする生菌製剤および乳酸菌含有食品 | |
| Hata et al. | Clinical effects of brown seaweed, Undaria pinnatifida (wakame), on blood pressure in hypertensive subjects | |
| JP2018532779A (ja) | 糖尿病及び腸疾患の治療又は予防における使用のためのフィーカリバクテリウムプラウスニッツィ及びデスルホビブリオピゲル | |
| CN110433230A (zh) | 霞多丽种子产品的治疗用途 | |
| EA037388B1 (ru) | Штамм lactobacillus paracasei для продуцирования линолевой кислоты с сопряженными связями, питательные и фармацевтические препараты, содержащие этот штамм, и их применение | |
| NZ525657A (en) | Use of a strain of lactobacillus reducing the risk factors involved in the metabolic syndrome | |
| US20230285477A1 (en) | Microbial therapy | |
| AU2011314299B2 (en) | Compositions and methods for augmenting kidney function | |
| RU2671221C2 (ru) | Композиции, содержащие смесь бактерий, включающую педиококк и лактобактерии, и способы для уменьшения эффектов алкоголя | |
| KR100404236B1 (ko) | 비만 또는 당뇨병 치료용 미생물 및 상기 미생물을포함하는 의약 조성물 | |
| KR20050010451A (ko) | 비만증 또는 당뇨병 예방 및/또는 치료용 미생물 | |
| Oyetayo et al. | Assessment of probiotic properties of a strain of Lactobacillus plantarum isolated from fermenting corn slurry (Ogi) | |
| JP2007186529A (ja) | 悪臭ガス放出減少方法 | |
| CN111560335A (zh) | 一株用于缓解哮喘的乳双歧杆菌及其应用 | |
| Wilkowska et al. | Influence of Human Age on the Prebiotic Effect of Pectin-Derived Ol-igosaccharides Obtained from Apple Pomace. Fermentation 2021, 7, 224 | |
| JP2024131845A (ja) | Ｓｃｆａまたは乳酸の産生方法 | |
| JP2690130B2 (ja) | 過酸化脂質減少剤 | |
| Matteuzzi et al. | Growth kinetics on oligo-and polysaccharides and promising features of three antioxidative 2 potential probiotic strains 3 | |
| Efrizal et al. | The Effects of Rusip on the Amount of Lactic Acid Bacteria in Gastrointestinal Tract | |
| Harnett | Biochemical individuality; assessment of the chronic refractory (or complex) patient: Part two: Urinary metabolites originating from intestinal microbiota | |
| Aumara et al. | PERMEATE BEVERAGE WITH |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |